Therapeutic Solutions International IncOTC Pink - Current Information:TSOI
- LAST PRICE0.0007
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0007 / 0.0007
- Day Range
- 52 Week Range
- Volume23,023,167
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSOI |
|---|---|---|
| 09:36 ET | 740000 | 0.0007 |
| 09:52 ET | 34350 | 0.000699 |
| 09:59 ET | 400 | 0.00065 |
| 10:01 ET | 500000 | 0.0007 |
| 10:14 ET | 140000 | 0.0007 |
| 11:24 ET | 11488 | 0.00065 |
| 11:38 ET | 3500000 | 0.0007 |
| 11:40 ET | 54600 | 0.0007 |
| 11:42 ET | 1750000 | 0.0007 |
| 11:47 ET | 508000 | 0.00065 |
| 11:58 ET | 1100000 | 0.00065 |
| 12:00 ET | 1000000 | 0.0006 |
| 12:03 ET | 125000 | 0.00069 |
| 12:05 ET | 12000 | 0.0007 |
| 12:07 ET | 250000 | 0.0006 |
| 12:12 ET | 10000 | 0.0007 |
| 12:20 ET | 50000 | 0.00065 |
| 12:34 ET | 200000 | 0.0007 |
| 12:39 ET | 500000 | 0.0007 |
| 12:50 ET | 40000 | 0.0007 |
| 12:54 ET | 1200000 | 0.0007 |
| 12:57 ET | 4000 | 0.0006 |
| 01:12 ET | 371 | 0.00065 |
| 01:26 ET | 250000 | 0.0006 |
| 01:30 ET | 421500 | 0.0007 |
| 01:32 ET | 371 | 0.0007 |
| 01:51 ET | 1000000 | 0.0007 |
| 02:06 ET | 20000 | 0.0007 |
| 02:49 ET | 25500 | 0.00065 |
| 02:54 ET | 50000 | 0.0007 |
| 03:30 ET | 142858 | 0.0007 |
| 03:39 ET | 520000 | 0.0007 |
| 03:59 ET | 75000 | 0.0007 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Therapeutic Solutions International Inc | 3.0M | -0.7x | --- |
Accustem Sciences Inc | 3.4M | -1.6x | --- |
Golden Valley Development Inc | 2.5M | 0.0x | --- |
Nemaura Medical Inc | 2.4M | -0.2x | --- |
Vycor Medical Inc | 2.7M | -6.5x | --- |
Innovative Eyewear Inc | 3.1M | -0.4x | --- |
Company Information
Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury, and for daily health. The Company's flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The Company also sells certain nutraceuticals. The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells.
Contact Information
- Headquarters
- 701 Wild Rose LaneELK CITY, ID, United States 83525
- Phone
- 760-295-7208
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Timothy Dixon
- Chief Scientific Officer
- Feng Lin
- Vice President - Business Development
- Famela Ramos
- Chief Medical Officer
- James Veltmeyer
- Director
- Thomas Ichim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
|---|---|
Revenue (TTM) | $83.7K |
Shares Outstanding | 4.2B |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 35.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,511.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
